XGN logo

XGN Exagen Inc.

NASDAQ Global Market · Medical - Diagnostics & Research · Healthcare

$3.61
-0.19 (-5.00%)

Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lu…

Market Cap: $92.10Mwww.exagen.com

Price

No data yet.

Social Signal Score

46
5d
—
30d
46
7 mentions
—
60d
46
7 mentions
—
90d
46
7 mentions
—
news: 7

Analyst Ratings

10 analysts
Buyconsensus
Strong Buy 0Buy 10Hold 0Sell 0Strong Sell 0
Avg price target$9.5+163.2%
Low $8Median $9.5High $11
Current Consensus

Revenue

$18.42M+334.57%
$4.24M$9.47M$14.71M$19.94M
Dec 2014Sep 2026

Analyst Estimates

FY2025
$-0.88
$-0.91–$-0.85
3 analysts
FY2026
$-0.72
$-0.74–$-0.69
4 analysts
FY2027
$-0.55
$-0.62–$-0.49
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
John Aballi
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
216
Beta
2.24
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
-5.74
www.exagen.com